// Evidence Grader
Claim grades, A through F
Every major genomics claim in this course gets a transparent grade — from clinically established interventions to outright misleading marketing. Use this dashboard to audit what's settled, what's preliminary, and what's hype.
A
Clinically established
B
Supported, context-specific
C
Promising, preliminary
D
Plausible, unproven
E
Popular, weak support
F
Misleading or false
Filtered:← Back to module
A
CHIP independently increases coronary heart disease risk
Jaiswal NEJM 2017; replicated in UK Biobank, MGB, MVP.
Module 11 · Clonal Hematopoiesis & Aging Genomes →A
TET2-mutant CHIP drives an IL-1β/NLRP3-dependent atherosclerosis phenotype
Fuster Science 2017 (mouse) + CANTOS post-hoc in TET2-CHIP humans.
Module 11 · Clonal Hematopoiesis & Aging Genomes →C
Routine CHIP screening of asymptomatic adults improves outcomes
No RCT evidence; CHRS gives risk stratification but no validated intervention.
Module 11 · Clonal Hematopoiesis & Aging Genomes →B
PARP-inhibitor exposure increases AML/MDS risk in patients with pre-existing CHIP
Suggested by ovarian-cancer pharmacovigilance + mechanistic rationale; absolute risk increase modest.
Module 11 · Clonal Hematopoiesis & Aging Genomes →